Pathogenesis of idiopathic calcium nephrolithiasis: Update 1997

Critical Reviews in Clinical Laboratory Sciences

Volumn 35, Issue 2, 1998, Pages 153-187

  Baggio, Bruno ^a   Plebani, Mario ^a   Gambaro, Giovanni ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Arachidonic acid; Band 3 protein; Bone metabolism; Delta 6 desaturase; Diet; Fish oil; Hypercalciuria; Oxalate; Pathogenesis; Renal lithiasis

Indexed keywords

ARACHIDONIC ACID; CALCIUM; CALCIUM ION; CALCIUM OXALATE; LINOLEIC ACID; MEMBRANE PHOSPHOLIPID; PROSTAGLANDIN;

CALCIUM OXALATE STONE; ERYTHROCYTE MEMBRANE; HYPERCALCIURIA; HYPEROXALURIA; KIDNEY TUBULE DISORDER; NEPHROLITHIASIS; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW;

CALCIUM; CALCIUM METABOLISM DISORDERS; FEMALE; HUMANS; KIDNEY; MALE; PEDIGREE; URINARY CALCULI;

EID: 0031748457     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408369891234183     Document Type: Review

References (164)

1. Nordin BEC, Hodgkinson A, Peacock M, et al. Urinary tract calculi. In: Hamburger J, Crosnier J, Grunfeld JP, eds. Nephrology. Pp. 1091-130. New York and Paris: Wiley, 1979.
2. Fleisch H. Inhibitors and promoters of stones. Kidney Int 1978; 13: 361-71.
3. Smith LH. Hyperoxaluria. In: Walker VR, Sutton RAL, Cameron ECB, Pak CYC, Robertson WG, eds. Urolithiasis. Pp. 405-9. New York: Plenum Press, 1988.
4. Finlayson B. Renal lithiasis in review. Urol Clin N Am 1974; 1: 181-212.
5. Robertson WG, Peacock M. The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron 1980; 26: 105-10.
6. Robertson WG, Peacock M Nordin BEC. Activity product in stone-forming and non stone-forming urine. Clin Sci 1968; 34: 579-94.
7. Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994; 46: 847-54.
8. Coe FL, Nakagawa Y Parks JH. Inhibitors within the nephron. Am J Kidney Dis 1991; 17: 407-13.
9. Ryall RL, Stapleton AMF. Urinary macromolecules in calcium oxalate stone and crystall matrix: good, bad, or indifferent. In: Khan SR, ed. Calcium oxalate in biological systems. Pp. 265-90. Boca Raton: CRC Press, 1995.
10. Khan SR. Where do the renal stone form and how? Ital J Mineral Electrolyte Metab 1996; 10: 75-82.
11. Gjaldbaek JC. Inhibition of chondroitin sulfate and heparin on the growth and agglomeration of calcium oxalate monohydrate crystals in vitro. Clin Chim Acta 1982; 120: 363-5.
12. Kok DJ, Papapoulos SE, Blomen LJMJ, et al. Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 1988; 34: 346-50.
13. Foye WO, Hong HS, Kin CM, et al. Degree of sulfation in mucopolysaccharide sulfates in normal and stone-forming urines. Invest Urol 1976; 14: 33-7.
14. Fellström B, Danielson BG, Lind E, et al. Enzymatic determination of urinary chondroitin sulfate: applications in renal stone disease and acromegaly. Eur J Clin Invest 1986; 16: 292-6.
15. Hess B. The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 1991; 5: 689-96.
16. Caudarella R, Simonelli L, Vasi V, et al. New in vitro methodological approaches to GAG study in idiopathic calcium lithiasis. Contrib Nephrol 1987; 58: 89-92.
17. Baggio B, Marzaro G, Gambaro G, et al. Glycosaminoglycan content, oxalate self-exchange and protein phosphorylation in erythrocytes of patients with "idiopathic" calcium oxalate nephrolithiasis. Clin Sci 1990; 79: 113-6.
18. Pak CYC. Physiological basis for absorptive and renal hypercalciuria. Am J Physiol 1979; 237: F415-23.
19. Minisola S, Rossi W, Pacitti TM, et al. Studies on citrate metabolism in normal subjects and kidney stone patients. Miner Electrol Metab 1989; 15: 303-8.
20. Baggio B, Gambaro G, Ossi E, et al. Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol 1983; 129: 1161-2.
21. Gambaro G, Baggio B, Favaro S, et al. Role de la mucoproteine de Tamm-Horsfall dans la lithogenese oxalique-calcique. Nephrologie 1984; 5: 171-2.
22. Jaeger P, Portmann L, Ginalsky JM, et al. Tubulopathy in nephrolithiasis: Consequence rather than cause. Kidney Int 1986; 29: 563-71.
23. Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 1978; 13: 334-60.
24. Parsons CL, Stauffer C Schmidt JD. Bladder-surface glycosaminolgycans: an effective mechanism of environmental adaptation. Science 1980; 208: 605-7.
25. Mandel N. Crystal-membrane interaction in kidney stone disease. J Am Soc Nephrol 1994; 5: S37-45.
26. Bigelow MW, Wiessner JH, Kleinman JG, et al. Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells. Am J Physiol 1997; 272: F55-F62.
27. Bigelow MW, Wiessner JH, Kleinman JG, et al. The dependence on membrane fluidity of calcium oxalate crystal attachment to IMCD membranes. Calcif Tissue Int 1997; 60: 375-9.
28. Scheid C, Koul H, Kennington L, et al. Oxalate-induced damage to renal tubular cells. Scanning Microsc 1995; 9: 1097-107.
29. Scheid C, Koul H, Hill WA, et al. Oxalate toxicity in LLC-PK1 cells, a line of renal epithelial cells. J Urol 1996; 155: 1112-6.
30. Scheid C, Koul H, Hill WA, et al. Oxalate toxicity in LLC-PK1 cells: role of free radicals. Kidney Int 1996; 49: 413-9.
31. Kumar S, Sigmon D Miller T. A new model of nephrolithiasis involving tubular dysfunction/injury. J Urol 1991; 146: 1384-9.
32. Khan SR. Mechanisms involved in calcium oxalate nephrolithiasis based on studies in animal model. Ital J Mineral Electrolyte Metab 1995; 9: 3-9.
33. Boyce WH. Organic matrix of human urinary concretions. Am J Med 1968; 45: 673-83.
34. Hackett RL, Shewock PN Khan SR. Cell injury associated calcium oxalate crystalluria. J Urol 1990; 144: 1535-8.
35. Khan SR. Where do the renal stones form and how. Ital J Mineral Electrolyte Metab 1996; 10: 75-82.
36. Anderson CK. Renal histological changes in stone formers and non-stone formers. In: Hodgkinson A, Nordin BEC, eds. Renal stone research symposium (Leeds 1968). Pp. 133-6. London: J & A Churchill, 1969.
37. Boyce WH, Willard JW. Intranephronic calculosis in the human kidney. In: Finlayson B, Hench LL, Smith LH, eds. Urolithiasis. Pp. 183. Physical Aspects. Washington, DC: Natl Acad Sci, 1972.
38. Burry AF, Axelsen RA, Trolove P, et al. Calcification in the renal medulla. Human Pathol 1976; 7: 435-49.
39. Lieske JC, Walsh-Reitz MM, Toback FG. Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. Am J Physiol 1992; 262: F622-30.
40. Koul H, Kennington L, Nair G, et al. Oxalate-induced initiation of DNA synthesis in LLC-PK1 cells, a line of renal epithelial cells. Biochem Biophys Res Commun 1994; 205: 1632-7.
41. Goswami A, Singhal PC, Wagner JD. Matrix modulates uptake of calcium oxalate crystals and cell growth of renal epithelial cells. J Urol 1995; 152: 206-11.
42. Hammes MS, Lieske JC Pawar S. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int 1995; 48: 501-9.
43. Koul H, Kennington L, Heneyman T, et al. Activation of c-myc gene mediates the mitogenic effects of oxalate in LLC-PK1 cell, a line of renal epithelial cells. Kidney Int 1996; 50: 1525-30.
44. Baggio B, Gambaro G, Marchini F, et al. Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet 1984; 2: 12-3.
45. Baggio B, Gambaro G, Marchini F, et al. An inheritable anomaly of red-cell oxalate transport in "primary" calcium nephrolithiasis correctable with diuretics. N Engl J Med 1986; 314: 599-604.
46. Gram HC. The heredity of oxalic urinary calculi. Acta Med Scand 1932; 78: 268-81.
47. Resnick M, Pridgen DB, Goodman HO. Genetic predisposition to calcium oxalate renal calculi. N Engl J Med 1968; 278: 1313-8.
48. Trinchieri A, Mandressi A Luongo P. Familial aggregation of renal calcium stone disease. J Urol 1988; 139: 478-81.
49. Marangella M, Fruttero B, Bruno M, et al. Hyperoxaluria in idiopathic calcium stone disease: further evidence of intestinal hyperabsorption of oxalate. Clin Sci 1982; 63: 465-75.
50. Hodgkinson A, Pyrah LN. The urinary excretion of calcium and inorganic phosphate in 344 patients with calcium stone of renal origin. Br J Surg 1958; 46: 10-8.
51. Coe FL, Parks JH Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 1979; 300: 337-40.
52. Harangi F, Mehes K. Family investigations in idiopathic hypercalciuria. Eur J Pediatr 1993; 160: 64-8.
53. Alacljem M, Modan M Lusky A. Idiopathic hypercalciuria: a familial generalized renal hyperexcretory state. Kidney Int 1983; 24: 549-54.
54. Robertson WG. Diet and calcium stones. Mineral Electrolyte Metab 1987; 13: 228-34.
55. Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis. Kidney Int 1988; 34: 544-55.
56. Bianchi G, Vezzoli G, Cusi D, et al. Abnormal red cell calcium pump in patients with idiopathic hypercalciuria. N Engl J Med 1988; 319: 897-901.
57. Carafoli E. The Ca pump of the plasma membrane. J Biol Chem 1992; 267: 2115-8.
58. Ferrari P, Tonelli L Ferrandi M. Volumes and Na transports in intact red blood cells, resealed ghosts and inside-out vesicles of Milan Hypertensive Rats. In: Bianchi G, Carofali E, Scarpa A, eds. Membrane pathology. Pp. 561-4. New York: Academy of Sciences, 1986.
59. Vezzoli G, Bianchi G. The erythrocyte as a model in the study of nephrolithiasis. Ital J Mineral Electrolyte Metab 1996; 10: 49-55.
60. Gambaro G, Marchini F, Piccoli A, et al. The abnormal red-cell oxalate transport is a risk factor for idiopathic calcium nephrolithiasis: a prospective study. J Am Soc Nephrol 1996; 7: 608-12.
61. Narula R, Sharma SH, Sidhu H, et al. Transport of oxalate in intact red blood cell can identify potential stone formers, Urol Res 1988; 16: 193.
62. Jenkins AD, Langley MJ Bobbitt MW. Red blood cell oxalate flux in patients with calcium urolithiasis. Urol Res 1988; 16: 209.
63. Motola JA, Urivetsky M, Molia L, et al. Transmembrane oxalate exchange: its relationship to idiopathic calcium oxalate nephrolithiasis. J Urol 1992; 147: 549-52.
64. Kato T, Yamakawa K Kawamura J. Oxalate influx rate in red blood cells in calcium oxalate nephrolithiasis. [Japanese]. Hinyokika Kiyo - Acta Urologica Japonica 1991; 37: 837-44.
65. Sigmon D, Sanjaya K, Carpenter MA, et al. Oxalate transport in renal tubular cells from normal and stone-forming animals. Am J Kidney Dis 1991; 17: 376-80.
66. Wandzilak TR, Calò L, D'Andre S, et al. Oxalate transport in cultured porcine renal epithelial cells. Urol Res 1992; 20: 341-5.
67. Hatch M, Freel RW Vaziri ND. Mechanisms of oxalate absorption and secretion across the rabbit distal colon. Pflügers Arch 1994; 426: 101-9.
68. Gambaro G, Petrarulo M, Nardelotto A, et al. Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis. Kidney Int 1995; 48: 1549-52.
69. Baggio B, Gambaro G, Borsatti A, et al. Relation between band 3 red blood cell protein and transmembrane oxalate flux in stone formers. Lancet 1984; ii: 223-4.
70. Baggio B, Bordin L, Gambaro G, et al. Evidence of a link between erythrocyte band 3 phosphorylation and anion transport in patients with "idiopathic" calcium oxalate nephrolithiasis. Miner Electrolyte Metab 1993; 19: 17-20.
71. Baggio B, Bordin L, Clari G, et al. Functional correlation between the Ser/Thr-phosphorylation of band-3 and band-3 mediated transmembrane anion transport in human erythrocytes. Biochim Biophys Acta 1993; 1148: 157-60.
72. Alper SL, Kopito RR Lodish HF. A molecular biological approach to the study of anion transport. Kidney Int 1987; 32(S23): 117-28.
73. Ullrich KJ, Papavassiliou F. Bicarbonate reabsorption in the papillary collecting duct of rats. Pflügers Arch 1981; 389: 271-5.
74. Drenckhan D, Schlüter K Allen DP, et al. Colocalization of band 3 with ankyrin and spectrin at the basal membrane of intercalated cells in the rat kidney. Science 1985; 230: 1287-9.
75. Borsatti A. Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 1991; 39: 1283-98.
76. Koul H, Menon M Scheid C. Oxalate and renal tubular cells: a complex interaction. Ital J Mineral Electrolyte Metab 1996; 10: 67-74.
77. Gambaro G, Vincenti M, Marchini F, et al. Abnormal urate transport in erythrocytes of idiopathic calcium nephrolithiasis: a possible link with hyperuricosuria. Clin Sci 1993; 85: 41-4.
78. Baggio B, Gambaro G, Marchin F, et al. Abnormal erythrocyte and renal frusemide-sensitive sodium transport in idiopathic calcium nephrolithiasis. Clin Sci 1994; 86: 239-43.
79. Xiao Quiang L, Tenibe V, Horowitz GM, et al. Increased intestinal vitamin D receptor in genetic hypercalciuric rats, a cause of intestinal hyperabsorption of calcium. J Clin Invest 1993; 91: 661-7.
80. Pak CYC, Ohata M Lawrence EC. The hypercalciurias: causes parathyroid functions, and diagnostic criteria. J Clin Invest 1974; 54: 387-400.
81. Olson S, Wang MG Carafoli E. Localization of two genes encoding plasma Ca-transporting ATPases to human chromosomes 1c125-32 and 12q21-23. Genomics 1991; 9: 629-41.
82. Vezzoli G, Reina MC, Cusi D, et al. Erythrocyte membrane calcium transport in patients with primary hyperparathyroidism. Biochem Biophys Res Commun 1994; 202: 1505-10.
83. Vezzoli G, Reina MC, Zerbi S, et al. (Ca-Mg)ATPase and calcium influx in erythrocytes of patients with idiopathic hypercalciuria. Biochem Biophys Res Commun 1995; 217: 1099-104.
84. Ghio L, Bianchi ML, Cecchetti V, et al. Free cytosolic calcium in children with idiopathic hypercalciuria. In: Linari F, Marangella M, Bruno M, eds. Pathogenesis and treatment of nephrolithiasis. Pp. 67-70. Basel: Karger, 1988.
85. Baggio B, Clari G, Marzaro G, et al. Altered red blood cell membrane protein phosphorylation in idiopathic calcium oxalate nephrolithiasis. IRCS Med Sci 1986; 14: 368-9.
86. Clari G, Baggio B, Marzaro G, et al. Phosphorylation of band 3 protein in nephrolithiasis. Ann N Y Acad Sci 1986; 488: 533-6.
87. Baggio B, Marzaro G, Gambaro G, et al. Effect of thiazides and amiloride on the phosphorylation status of red cell membrane anion carrier. In: Diuretics: basic, pharmacological, and clinical aspects. Andreucci VE, Dal Canton A, eds. Pp. 65-7. Boston: Martinus Nijhoff Publishing, 1987.
88. 3H)bumetanide binding to avian erythrocyte membranes. Correlation with activation and deactivation of Na/K/2Cl cotransport. J Biol Chem 1990; 265: 20747-56.
89. Baggio B, Bordin L, Gambaro G, et al. Evidence of a link between erythrocyte band 3 phosphorylation and anion transport in patients with "idiopathic" calcium oxalate nephrolithiasis. Miner Electrolyte Metab 1993; 19: 17-20.
90. Baggio B, Bordin L, Clari G, et al. Functional correlation between the Ser/Thr-phosphorylation of band-3 and band-3 mediated transmembrane anion transport in human erythrocytes. Biochim Biophys Acta 1993; 1148: 157-60.
91. Gambaro G, Vincenti M, Baggio B, et al. Oxalate transport in the intestinal epithelium and in the erythrocyte. J Am Soc Nephrol 1993; 14: 707.
92. Baggio B, Gambaro G, Marzaro G, et al. Effects of the oral administration of glycosamino-glycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis. Eur J Clin Pharmacol 1991; 40: 237-40.
93. Pelech SL, Vance DE. Signal transduction via phosphatidylcholine cycles. TIBS 1989; 14: 28-30.
94. Liscovitch M, Cantley LC. Lipid second messengers. Cell 1994; 77: 329-34.
95. Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1994; 1212: 26-42.
96. Buck AC, Lote CJ Sampson WF. The influence of renal prostaglandins on urinary calcium excretion in idiopathic urolithiasis. J Urol 1983; 129: 421-6.
97. 2 in urinary stone formation. J Urol 1988; 139: 549-51.
98. 2 in patients with idiopathic hypercalciuria is a primary phenomenon. Clin Sci 1992; 83: 75-80.
99. Buck AC, Davies RL Harrison T. The protective role of eicosapentaenoic acid (EPA) in the pathogenesis of nephrolithiasis. J Urol 1991; 146: 188-94.
100. Rothwell PJN, Green R, Blacklock NJ, et al. Does fish oil benefit stone formers? J Urol 1993; 150: 1391-4.
101. Baggio B, Gambaro G, Oliva O, et al. Calcium oxalate nephrolithiasis: an easy way to detect an imbalance between promoting and inhibiting factors. Clin Chim Acta 1982; 124: 149-155.
102. Baggio B, Gambaro G, Cicerello E, et al. Urinary excretion of glycosaminoglycans in urological disease. Clin Biochem 1987; 20: 449-50.
103. Baggio B, Gambaro G, Marchini F, et al. Correction of erythrocyte abnormalities in idiopathic calcium oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans Lancet 1991; 338: 403-4.
104. Palmoski MJ, Brandt KD. Effect of some nonsteroidal antiinflammatory drugs on proteoglycan metabolism and organization in canine cartilage. A rthritis Rheum 1980; 23: 1010-20.
105. Arumugham R, Bose SM. Effect of indomethacin and naproxen on the metabolism of glycosaminoglycans. Scand J Rheumatol 1980; 11: 225-9.
106. Baggio B, Gambaro G, Zambon S, et al. Anomalous phospholipid n-6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am Soc Nephrol 1996; 7: 613-20.
107. Engelmann B, Streich S, Schonthier UM, et al. Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochim Biophys Acta 1992; 1165: 32-7.
108. Kawashima Y, Mizuguchi H Kozuka H. Modulation by dietary oils and clofibric acid of arachidonic acid content in phosphatidylcholine in liver and kidney of rat. Effects on prostaglandin formation in kidney. Biochim Biophys Acta 1994; 1210: 187-94.
109. Brenner RR. Factors influencing fatty acid chain elongation and desaturation. In: Vergrosen AJ, Crawford M, eds. The role of fats in human nutrition. 2nd ed. Pp. 45-79. London: Academic Press, 1989.
110. Kurokawa K. Calcium-regulating hormones and the kidney. Kidney Int 1987; 32: 760-71.
111. Stokes JB. Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol 1981; 240: F471-80.
112. Molony DA, Reeves WB Andreoli TE. Na:K:2Cl cotransport and the thick ascending limb. Kidney Int 1989; 36: 418-26.
113. 2) inhibits NaK2Cl cotransport in cultured mouse medullary thick ascending limb. J Am Soc Nephrol 1991; 2: 428.
114. Fischer S. Dietary polyunsaturated fatty acids and eicosanoid formation in humans. Adv Lip Res 1989; 23: 169-98.
115. Davidson J. Lipid metabolism. Curr Opin Lipidol 1995; 6: U65-6.
116. Popp-Snijders C: Assessment of compliance to changes in dietary fatty acids. Diab Nutr Metab 1991; 4: 155-63.
117. Marangoni F, Angeli MT, Colli S, et al. Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochem Biophys Acta 1993; 1210: 55-62.
118. Düsing R, Struck A, Gobel BO, et al. Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 1990; 38: 315-9.
119. Pagnan A, Corrocher R, Ambrosio GB, et al. Effects of olive oil-rich diet on erythrocyte membrane lipid composition and cation transport systems. Clin Sci 1989; 76: 87-93.
120. Engelmann B, Op Den Kamp JAF Roelofsen B. Replacement of molecular species of phosphatidylcholine: influence on erythrocyte Na transport. Am J Physiol 1990; 258: C682-91.
121. Dwight JFSt J, Mendes Ribeiro AC Hendry BM. Membrane incorporation of non-esterified fatty acids and effects on the sodium pump of human erythrocytes. Clin Sci 1992; 82: 99-104.
122. Gambaro G, Marchini F, Vincenti M, et al. Is hyperprostaglandinuria a primitive phenomenon in idiopathic calcium nephrolithiasis? J Am Soc Nephrol 1994; 5: 862.
123. Ghazali A, Hardy-Yverneau P, Bataille P, et al. Bone and idiopathic calcium nephrolithiasis. Ital J Mineral Electrolyte Metab 1996; 10: 83-94.
124. Bataille P, Charansol G Gregoire I. Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones. J Urol 1983; 130: 218-23.
125. 2 D levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982; 72: 25-32.
126. Coe FL, Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol 1984; 247: F1-13.
127. Lieberman UA, Sperling O, Atsmon A, et al. Metabolic and calcium kinetic studies in idiopathic hypercalciuria. 7 Clin Invest 1968; 47: 2580-9.
128. Messa P, Mioni G Montanaro D. About a primitive osseous origin of the so-called renal hypercalciuria. Contr Nephrol 1987; 58: 106-10.
129. Bataille P, Achard JM Fournier A. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39: 1193-205.
130. Pacifici R, Rothstein M Pifas L. Increased monocyte interleukin 1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 1990; 71: 138-45.
131. Wachman A, Bernstein DS. Diet and osteoporosis. Lancet 1968; i: 958-9.
132. Lemann J Jr, Litzow JR Lennon EJ. The effect of chronic acid loads in normal man: Further evidence for the participation of bone mineral in the defence against chronic metabolic acidosis. J Clin Invest 1966; 45: 1608-14.
133. Lemann J. Urinary calcium excretion and net acid excretion: effects of dietary protein, carbohydrate and calories. In: Schwille PO, Smith LH, Robertson WG, Finlayson B, eds. Urolithiasis and related clinical research. Pp. 53-60. New York: Plenum Press, 1985.
134. Nordin RW, Jee WSS High WB. Prostaglandins, Leukotrienes and Essential Fatty Acids 1990; 41: 139-44.
135. Weisinger JR, Alonzo E Bellorin-Font E. Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 1996; 49: 244-50.
136. Pacifici R, Rifers L Teitlbaum S, et al. Spontaneous release of interleukin 1 from human blood monocytes reflects bone resorption in idiopathic osteoporosis. Proc Natl Acad Sci USA 1987; 84: 4616-20.
137. Ghazali A, Fuentes V, Desaint C, et al. Low bone mineral density and peripheral blood monocyte activation in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997; 28: 32-8.
138. 3. J Clin Invest 1993; 91: 1731-42.
139. Caughey GE, Mantzioris E, Gibson RA, et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996; 63: 116-22.
140. Meydani SN, Lichtenstein AH, Cornwall S, et al. Immunological effects of national cholesterol education panel (NCEP) step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 1993; 92: 105-13.
141. Claassen N, Potgieter HC, Seppa M, et al. Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks, total urinary hydroxyproline, and bone calcium content. Bone 1995; 16: 385S-92S.
142. Buckley BJ, Whorton AR. Arachidonic acid stimulates protein tyrosine phosphorylation in vascular cells. Am J Physiol 1995; 269: C1489-95.
143. Rizzo MT, Carlo-Stella C. Arachidonic acid mediates interleuchin-1 and tumor necrosis factor-α-induced activation of the c-jun amino-terminal kinases in stromal cells. Blood 1996; 88: 3792-800.
144. Hunter T, Karin M. The regulation of transcription by phosphorylation. Cell 1992; 70: 375-87.
145. Rizzo MT, Boswell HS, Mangoni L, et al. Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-α: evidence for a tyrosine-kinase dependent process. Blood 1995; 86: 2967-73.
146. Milliner DS. Epidemiology of calcium oxalate urolithiasis in man. In: Khan SR, ed. Calcium oxalate in biological systems. Pp. 169-88. Boca Raton: CRC Press, 1995.
147. Yoshida O. Epidemiology of stones in Japan. Jpn J Urol 1979; 7: 975-83.
148. Robertson WG. Epidemiology of urinary stone disease. Urol Res 1990; 18(Suppl 1): 3-8.
149. Schwille PO, Herrmann U. Environmental factors in the pathophysiology of recurrent idiopathic calcium urolithiasis (RCU) with emphasis on nutrition. Urol Res 1992; 20: 72-83.
150. Andersen DA. Historical and geographical differences in the pattern of incidence of urinary stones considered in relation to possible aetiological factors. In: Hodgkinson A, Nordin BEC, eds. Renal stone research symposium (Leeds 1968). Pp. 7-31. London: J & A Churchill, 1969.
151. Menon M., Mahle CJ. Oxalate metabolism and renal calculi. J Urol 1982; 127: 148-51.
152. Hess B, Ackermann D, Essig M, et al. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J Clin Endocrinol Metab 1995; 80: 1916-21.
153. Kok DJ, Iestra JA, Doorenbos CJ et al. The effects of dietary excess in animal protein and sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 1990; 4: 861-7.
154. Simpson DP. Citrate excretion: a window on renal metabolism. Am J Physiol 1983; 244: F223-34.
155. Hess B, Zipperle L Jaeger Ph. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 1993; 265: F784-91.
156. Gibson RA, Sinclair AJ. Are eskimos obligated carnivores? Lancet 1981; i: 1100-1.
157. Iguchi M, Kataoka K, Kohri K, et al. Nutritional risk factors in calcium stone disease in Japan. Urol Int 1984; 39: 32-5.
158. Masai M, Ito H, Kotake T. The effect of dietary intake on urinary oxalate excretion in calcium renal stone formers. Br J Urol 1995; 76: 692-6.
159. Hoffman P, Mest H-J. What about the effects of dietary lipids on endogenous prostanoid synthesis? A state of the art review. Biomed Biochim Acta 1987; 46: 639-50.
160. Kromann N, Green A. Epidemiological studies in the U pernavik district, Greenland. Acta Med Scand 1980; 208: 401-6.
161. Dyerherg J, Bang HO, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 1978; ii: 117-9.
162. Throngren M, Gustafson A. Effects of 11 weeks increase in diet eicosapentaenoic acid on bleeding time, lipids and platelet aggregation. Lancet 1981; ii: 1190-4.
163. Hwang DH, Carrol AE. Decreased formation of prostaglandins derived from arachidonic acid by dietary liolenate in rats. Am J Clin Nutr 1980; 33: 523-30.
164. Hwang DH, Bourdeau M Chanmugan P. Dietary linolenic acid and long-chain n-3 fatty acids: Comparison of effects on arachidonic acid metabolism in rats. J Nutr 1988; 118: 427-37.